---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-119165"
form_type: "8-K"
ticker: "NWBO"
cik: "0001072379"
company_name: "NORTHWEST BIOTHERAPEUTICS INC"
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T00:50:14.157850+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NWBO enters $11M loan with Streeterville Capital; 8% interest, 24-month maturity

## Summary
- Loan amount $11,005,000 from Streeterville Capital; 24-month maturity; repayments begin Nov 2024.
- Interest rate 8% per annum; 10% original issue discount; prepayment allowed with 10% charge.
- Loan amortized in 12 equal monthly installments at 110% of pro rata principal plus accrued interest.
- Proceeds used for ongoing business operations; customary default provisions included.

## SEC filing metadata
- accession: 0001104659-23-119165
- form_type: 8-K
- ticker: NWBO
- cik: 0001072379
- company_name: NORTHWEST BIOTHERAPEUTICS INC
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/0001104659-23-119165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/tm2330851d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-119165
- JSON: https://secwatch.observer/filing/0001104659-23-119165.json
- Plain text: https://secwatch.observer/filing/0001104659-23-119165.txt

## Key facts
- Debt Financings
  NORTHWEST BIOTHERAPEUTICS INC incurred loan of $11,005,000 with Streeterville Capital, LLC at 8% per annum maturing 24 months.
  - Instrument: loan
  - Principal: $11,005,000
  - Counterparty: Streeterville Capital, LLC
  - Rate: 8% per annum
  - Maturity: 24 months
  - Event: incurrence
  source text: On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 24 months. Repayments do not start until November 10, 2024. Following November 10, 2024, the Loan Agreement will be amortized in 12 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/0001104659-23-119165-index.htm
- Material Agreements
  NORTHWEST BIOTHERAPEUTICS INC entered into Commercial Loan Agreement and Note with Streeterville Capital, LLC valued at $11,005,000 (effective 2023-11-10).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Streeterville Capital, LLC
  - Value: $11,005,000
  - Effective: 2023-11-10
  source text: On November 10, 2023, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1072379/000110465923119165/0001104659-23-119165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.